218 related articles for article (PubMed ID: 32312102)
1. Impact of mandated prospectively reported apparent diffusion coefficient values on the rates of positivity for clinically significant prostate cancer by PI-RADS score.
Shaish H; Casals R; Ahmed F; Makkar J; Wenske S
Acta Radiol; 2021 Jan; 62(1):139-144. PubMed ID: 32312102
[TBL] [Abstract][Full Text] [Related]
2. Which clinical and radiological characteristics can predict clinically significant prostate cancer in PI-RADS 3 lesions? A retrospective study in a high-volume academic center.
Hermie I; Van Besien J; De Visschere P; Lumen N; Decaestecker K
Eur J Radiol; 2019 May; 114():92-98. PubMed ID: 31005183
[TBL] [Abstract][Full Text] [Related]
3. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
[No Abstract] [Full Text] [Related]
4. Contribution of Dynamic Contrast-enhanced and Diffusion MRI to PI-RADS for Detecting Clinically Significant Prostate Cancer.
Tavakoli AA; Hielscher T; Badura P; Görtz M; Kuder TA; Gnirs R; Schwab C; Hohenfellner M; Schlemmer HP; Bonekamp D
Radiology; 2023 Jan; 306(1):186-199. PubMed ID: 35972360
[TBL] [Abstract][Full Text] [Related]
5. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
6. Risk of Clinically Significant Prostate Cancer Associated With Prostate Imaging Reporting and Data System Category 3 (Equivocal) Lesions Identified on Multiparametric Prostate MRI.
Sheridan AD; Nath SK; Syed JS; Aneja S; Sprenkle PC; Weinreb JC; Spektor M
AJR Am J Roentgenol; 2018 Feb; 210(2):347-357. PubMed ID: 29112469
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Prostate Imaging Reporting and Data System (PI-RADS) version 1 and version 2 and combination with apparent diffusion coefficient as a predictor of biopsy outcome.
Ryznarová Z; Keller J; Záleský M; Zachoval R; Čapek V; Malikova H
Neuro Endocrinol Lett; 2019 Mar; 40(1):41-50. PubMed ID: 31184822
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
Lim CS; Abreu-Gomez J; Carrion I; Schieda N
AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
[No Abstract] [Full Text] [Related]
9. Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection and Investigation of Multiparametric MRI-derived Markers.
Yilmaz EC; Shih JH; Belue MJ; Harmon SA; Phelps TE; Garcia C; Hazen LA; Toubaji A; Merino MJ; Gurram S; Choyke PL; Wood BJ; Pinto PA; Turkbey B
Radiology; 2023 May; 307(4):e221309. PubMed ID: 37129493
[TBL] [Abstract][Full Text] [Related]
10. MRI-Ultrasound Fusion Targeted Biopsy of Prostate Imaging Reporting and Data System Version 2 Category 5 Lesions Found False-Positive at Multiparametric Prostate MRI.
Sheridan AD; Nath SK; Aneja S; Syed JS; Pahade J; Mathur M; Sprenkle P; Weinreb JC; Spektor M
AJR Am J Roentgenol; 2018 May; 210(5):W218-W225. PubMed ID: 29489409
[TBL] [Abstract][Full Text] [Related]
11. Initial experience of magnetic resonance imaging/ultrasonography fusion transperineal biopsy: Biopsy techniques and results for 75 patients.
Tae JH; Shim JS; Jin HJ; Yoon SG; No TI; Kim JY; Kang SH; Cheon J; Kang SG
Investig Clin Urol; 2018 Nov; 59(6):363-370. PubMed ID: 30402568
[TBL] [Abstract][Full Text] [Related]
12. Retrospective comparison of direct in-bore magnetic resonance imaging (MRI)-guided biopsy and fusion-guided biopsy in patients with MRI lesions which are likely or highly likely to be clinically significant prostate cancer.
Venderink W; van der Leest M; van Luijtelaar A; van de Ven WJM; Fütterer JJ; Sedelaar JPM; Huisman HJ
World J Urol; 2017 Dec; 35(12):1849-1855. PubMed ID: 28871396
[TBL] [Abstract][Full Text] [Related]
13. Effects of the addition of quantitative apparent diffusion coefficient data on the diagnostic performance of the PI-RADS v2 scoring system to detect clinically significant prostate cancer.
Moraes MO; Roman DHH; Copetti J; de S Santos F; Agra A; Noronha JAP; Carvalhal G; Neto EJD; Zanon M; Baldisserotto M; Hochhegger B
World J Urol; 2020 Apr; 38(4):981-991. PubMed ID: 31175458
[TBL] [Abstract][Full Text] [Related]
14. PI-RADS v2 and ADC values: is there room for improvement?
Jordan EJ; Fiske C; Zagoria R; Westphalen AC
Abdom Radiol (NY); 2018 Nov; 43(11):3109-3116. PubMed ID: 29550953
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Analysis of Diffusion Weighted Imaging May Improve Risk Stratification of Prostatic Transition Zone Lesions.
Engel H; Oerther B; Reisert M; Kellner E; Sigle A; Gratzke C; Bronsert P; Krauss T; Bamberg F; Benndorf M
In Vivo; 2022; 36(5):2323-2331. PubMed ID: 36099133
[TBL] [Abstract][Full Text] [Related]
16. Who can safely evade a magnetic resonance imaging fusion-targeted biopsy (MRIFTB) for prostate imaging reporting and data system (PI-RADS) 3 lesion?
Kim M; Ryu H; Lee HJ; Hwang SI; Choe G; Hong SK
World J Urol; 2021 May; 39(5):1463-1471. PubMed ID: 32696126
[TBL] [Abstract][Full Text] [Related]
17. PI-RADS Upgrading Rules: Impact on Prostate Cancer Detection and Biopsy Avoidance of MRI-Directed Diagnostic Pathways.
de Oliveira Correia ET; Purysko AS; Paranhos BM; Shoag JE; Padhani AR; Bittencourt LK
AJR Am J Roentgenol; 2024 May; 222(5):e2330611. PubMed ID: 38353450
[No Abstract] [Full Text] [Related]
18. Clinically insignificant prostate cancer suitable for active surveillance according to Prostate Cancer Research International: Active surveillance criteria: Utility of PI-RADS v2.
Yim JH; Kim CK; Kim JH
J Magn Reson Imaging; 2018 Apr; 47(4):1072-1079. PubMed ID: 28901655
[TBL] [Abstract][Full Text] [Related]
19. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI?
Polanec SH; Bickel H; Wengert GJ; Arnoldner M; Clauser P; Susani M; Shariat SF; Pinker K; Helbich TH; Baltzer PAT
Clin Radiol; 2020 Feb; 75(2):157.e1-157.e7. PubMed ID: 31690449
[TBL] [Abstract][Full Text] [Related]
20. Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol.
Luzzago S; Musi G; Catellani M; Russo A; Di Trapani E; Mistretta FA; Bianchi R; Cozzi G; Conti A; Pricolo P; Ferro M; Matei DV; Mirone V; Petralia G; de Cobelli O
Urol Int; 2018; 101(1):56-64. PubMed ID: 29734177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
